Cerebral Palsy – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cerebral Palsy – Drugs in Development, 2021, provides an overview of the Cerebral Palsy (Central Nervous System) pipeline landscape.

Cerebral palsy is a group of disorders that can involve brain and nervous system functions, such as movement, learning, hearing, seeing, and thinking. Symptoms include muscles that are very tight and do not stretch, abnormal walk (gait), arms tucked in toward the sides, knees crossed or touching, legs make scissors movements, walk on the toes, speech problems (dysarthria), hearing or vision problems and pain. Treatment includes anticonvulsants and muscle relaxants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cerebral Palsy – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Cerebral Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cerebral Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 1, 1, 7, 1 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 1 molecules, respectively.

Cerebral Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Cerebral Palsy (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Cerebral Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Cerebral Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Cerebral Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Cerebral Palsy (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cerebral Palsy (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cerebral Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Baylx Inc

BrainRepair UG

Cell Tech Pharmed Co

CytoDel Inc

FamiCord Group

Gene Techno Science Co Ltd

Help Therapeutics

Hope Biosciences LLC

iCELL Biotechnology Co Ltd

Kashiv BioSciences LLC

Meridigen Biotech Co Ltd

MGC Pharmaceuticals Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cerebral Palsy - Overview

Cerebral Palsy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cerebral Palsy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cerebral Palsy - Companies Involved in Therapeutics Development

Baylx Inc

BrainRepair UG

Cell Tech Pharmed Co

CytoDel Inc

FamiCord Group

Gene Techno Science Co Ltd

Help Therapeutics

Hope Biosciences LLC

iCELL Biotechnology Co Ltd

Kashiv BioSciences LLC

Meridigen Biotech Co Ltd

MGC Pharmaceuticals Ltd

Revance Therapeutics Inc

Cerebral Palsy - Drug Profiles

ANGES-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BXU-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CepaCann - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyto-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-128 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NOS for Neurodegenerative Diseases and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Asherman Syndrome, Parkinson's Disease, Bronchial Fistula, Spastic Cerebral palsy, Primary Ovarian Insufficiency and Graft versus Host Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cerebral Palsy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cerebral Palsy and Pervasive Developmental Disorder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMC-11910 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vartocell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cerebral Palsy - Dormant Projects

Cerebral Palsy - Product Development Milestones

Featured News & Press Releases

May 01, 2020: Revance and Mylan biosimilar to Botox program decision to extend beyond April 30, 2020

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cerebral Palsy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Cerebral Palsy – Pipeline by Baylx Inc, 2021

Cerebral Palsy – Pipeline by BrainRepair UG, 2021

Cerebral Palsy – Pipeline by Cell Tech Pharmed Co, 2021

Cerebral Palsy – Pipeline by CytoDel Inc, 2021

Cerebral Palsy – Pipeline by FamiCord Group, 2021

Cerebral Palsy – Pipeline by Gene Techno Science Co Ltd, 2021

Cerebral Palsy – Pipeline by Help Therapeutics, 2021

Cerebral Palsy – Pipeline by Hope Biosciences LLC, 2021

Cerebral Palsy – Pipeline by iCELL Biotechnology Co Ltd, 2021

Cerebral Palsy – Pipeline by Kashiv BioSciences LLC, 2021

Cerebral Palsy – Pipeline by Meridigen Biotech Co Ltd, 2021

Cerebral Palsy – Pipeline by MGC Pharmaceuticals Ltd, 2021

Cerebral Palsy – Pipeline by Revance Therapeutics Inc, 2021

Cerebral Palsy – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Cerebral Palsy, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports